Nuformix PLC (LSE:NFX) has updated investors on its NXP004 programme which is developing novel forms of AstraZeneca’s Olaparib (Lynparza) cancer drug.
Lynparza generated US$2.7bn of sales in 2021 though it has presented challenges historically in terms of 'pill burden' and low olaprib bioavailability.
Nuformix noted that it has so far filed two patent applications covering novel cocrystal forms of olaparib with the potential of protection out to 2041.
These novel forms have undergone tests that demonstrate the two lead NXP004 cocrystals selected out-perform Lynparza, both in terms of rate and extent of dissolution and release of olaparib, the company said, highlighting these positive results.
"I'm delighted with the results of the head-to-head dissolution studies, which exceeded my expectations and have demonstrated first-time that the lead NXP004 cocrystals offer significant scope for enhanced performance versus Lynparza, for which biorelevant dissolution data is not in the public domain,” said Nuformix executive director Dr Dan Gooding in a statement.
“The NXP004 cocrystals studied demonstrate some of the best dissolution performance I've seen from application of the technology - a step-change in dissolution performance, yet they appear to lack any of the common drawbacks that can hamper development of cocrystal-based products, which is surprising.
“These new data strongly support progression of the programme and we will now look to translate these enhancements into an in-vivo setting, which if successful will position the company well for commencing partnering discussions with multiple potential partners identified," he added.
Nuformix told investors it will now look at the design of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of Olaparib, ahead of the commencement of talks with multiple potential commercialisation partners.